Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIORA THERAPEUTICS, INC.BIOR · Entity 85047 | Director | June 05, 2024 | June 06, 2024 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | February 07, 2024 | February 07, 2024 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 25, 2024 | May 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIORA THERAPEUTICS, INC.
Report date June 05, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,746 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 30,746 F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2034-06-05 | Direct | 12,500 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500 F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2029-08-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
RIGEL PHARMACEUTICALS INC
Report date May 25, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2024-05-25 transaction · row 1
1 source rowRow 1 · 2024-05-25 · Grant · Acquired 25,000 · Balance 100,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2034-05-25 | Direct | 30,000 |
Reported balance
After 2024-05-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-25 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 6, 2024 16:33 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000950170-24-069927 · ownership.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-05 F2 · derivative.exercise_date: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 16:33 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069927 · ownership.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,746 F1 · shares: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000905148-24-001653 · form4.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-25 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001653 · form4.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:07 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0000950170-23-028599 · ownership.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:07 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-028599 · ownership.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,246 F1 · shares: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-23-034283 · form4.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-034283 · form4.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:06 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Disposition to issuerSeries X Preferred Stock | 44 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000970 · doc4.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. F2 · price: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:31 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 148,810 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-22-023092 · doc4.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,810 Underlying: Common Stock · 148,810 shares Expires 2032-06-15 F2 · deemedExecutionDate: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:31 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 96,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023092 · doc4.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,672 F1 · shares: Represents 96,154 restricted stock units, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001140361-22-020302 · form4.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-20 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020302 · form4.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 51,724 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000899243-21-024206 · doc4.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,724 Underlying: Common Stock · 51,724 shares Expires 2031-06-14 F2 · deemedExecutionDate: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantCommon Stock | 29,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-024206 · doc4.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,518 F1 · shares: Represents 29,183 restricted stock units, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:59 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001179110-21-005768 · edgar.xml · derivative · entry 2 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-19 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:59 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005768 · edgar.xml · nonDerivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:53 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001179110-20-006133 · edgar.xml · derivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:19 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001179110-19-006701 · edgar.xml · derivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 17, 2018 Filed May 19, 2018 01:36 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001179110-18-007153 · edgar.xml · derivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| August 21, 2017 Filed Aug 24, 2017 00:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001179110-17-011797 · edgar.xml · derivative · entry 1 Kotzin Brian L. · CIK 0001715332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-08-21 F1 · derivative.exercise_date: The Option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.